<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01958775</url>
  </required_header>
  <id_info>
    <org_study_id>REB-07-0394</org_study_id>
    <nct_id>NCT01958775</nct_id>
  </id_info>
  <brief_title>Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Like Peptide 2</brief_title>
  <official_title>Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Like</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To assess whether Glucagon like peptide 2 (GLP-2) affects lipoprotein production (study&#xD;
           A)&#xD;
&#xD;
        2. To assess whether GLP-2 affects the release of preformed chylomicrons (study B)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study A: Using constant feeding with a nasoduodenal tube and stable isotope infusion,&#xD;
      mathematical modelling will be utilised to measure lipoprotein production and clearance. The&#xD;
      lipoproteins assessed will be apoB-100 from the liver and apoB-48 from the intestine.&#xD;
&#xD;
      StudyB: Volunteers will be given a liquid meal with retinyl palmitate (vitamin A) to label&#xD;
      chylomicrons made from the meal. 7 hours later they will be given GLP-2 or placebo.&#xD;
      Measurements of plasma and TRL(triglyceride rich lipoprotein) triglyceride and TRL retinyl&#xD;
      palmitate will be carried out to see whether GLP-2 increases these parameters.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lipoprotein production and clearance rate</measure>
    <time_frame>10 hours</time_frame>
    <description>ApoB 100 and ApoB 48 production and clearance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma and TRL triglyceride and TRL retinyl palmitate</measure>
    <time_frame>10 hours</time_frame>
    <description>Measurements will be carried out hourly after ingestion of meal and then every 15-30 minutes thereafter to see if GLP-2 increases these parameters compared to placebo.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>GLP=2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>active treatment with a single dose of GLP-2 (1500mcg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-2</intervention_name>
    <description>single subcutaneous dose of 1500mcg</description>
    <arm_group_label>GLP=2</arm_group_label>
    <other_name>glucagon like peptide 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion Criteria:&#xD;
&#xD;
               1. Men and women, aged 18 to 60 years&#xD;
&#xD;
               2. Body mass index 20 kg/m2 to 30 kg/m2&#xD;
&#xD;
               3. Hemoglobin above 130g/L.&#xD;
&#xD;
               4. Normal glucose tolerance in response to a 75g, 2-hr oral glucose tolerance test&#xD;
                  (OGTT)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Subject has a history of hepatitis/hepatic disease that has been active within the&#xD;
             previous two years.&#xD;
&#xD;
             2. Any significant active (over the past 12 months) disease of the gastrointestinal,&#xD;
             pulmonary, neurological, renal (Cr &gt; 1.5 mg/dL), genitourinary, hematological systems,&#xD;
             or has severe uncontrolled treated or untreated hypertension (sitting diastolic BP &gt;&#xD;
             100 or systolic &gt; 180) or proliferative retinopathy 3. History of diabetes or OGTT&#xD;
             indicative of diabetes or impaired glucose tolerance.&#xD;
&#xD;
             4. Any history of ischemic heart disease or clinically significant, active,&#xD;
             cardiovascular history including a history of arrhythmia's or conduction delays on&#xD;
             ECG, unstable angina, or decompensated heart failure.&#xD;
&#xD;
             5. Abnormal liver or thyroid function tests 6. Current addiction to alcohol or&#xD;
             substances of abuse as determined by the investigator.&#xD;
&#xD;
             7. Mental incapacity, unwillingness or language barrier precluding adequate&#xD;
             understanding or cooperation 8. Taking any prescription or non-prescription&#xD;
             medications at the time of the study 9. Having donated blood three months prior to and&#xD;
             three months post study procedures 10. A pregnancy test will be performed 1 to 3 days&#xD;
             prior to each study in all female research participants. Those who test positive for&#xD;
             pregnancy will be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>October 7, 2013</study_first_submitted>
  <study_first_submitted_qc>October 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2013</study_first_posted>
  <last_update_submitted>March 6, 2015</last_update_submitted>
  <last_update_submitted_qc>March 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lipoproteins, apoB, GLP-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

